For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...

Researchers investigated whether induction chemotherapy improves PFS and OS in patients with locally advanced cervical cancer ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...

The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

Patients with EGFR-mutant, oligometastatic NSCLC who received radiotherapy plus icotinib had longer overall and progression-free survival than those who received icotinib alone.

Long-term results support the use of capmatinib in patients with previously treated or untreated METex14 NSCLC, according to researchers.

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...